The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.
 
Jennifer J. Knox
Honoraria - AstraZeneca; Incyte; Ipsen; Roche Canada
Consulting or Advisory Role - AstraZeneca/MedImmune; Incyte; Ipsen; Lilly; Merck
Research Funding - AstraZeneca; Ipsen; Merck
Expert Testimony - AstraZeneca; Incyte
 
Elizabeth M. Jaffee
Stock and Other Ownership Interests - ABMETA Therapeutics; Adventris
Consulting or Advisory Role - Achilles Therapeutics; Dragonfly Therapeutics; Medically Home; Mestag Therapeutics; NeoTX; NEUVOGEN; SURGE Therapeutics
Research Funding - Breast Cancer Research Foundation; Bristol-Myers Squibb; Lucence Diagnostics; Roche
Patents, Royalties, Other Intellectual Property - I developed GVAX which is being tested in the clinics. It was licensed to Adoro Biotech. IF it becomes commercial I will have the potential to receive royalties. Also, I have received milestone payments yearly.
Other Relationship - Break Through Cancer; CPRIT; Parker Institute; Parker Institute
 
Grainne M. O'Kane
Honoraria - AstraZeneca; Incyte; MSD Oncology; Roche; Servier/Pfizer
Consulting or Advisory Role - AstraZeneca Canada; Incyte; Roche; Servier
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - MSD
 
Daniel King
Stock and Other Ownership Interests - Illumina
Honoraria - Ipsen; Omni Health; Omni Health; Skysis
 
Dan Laheru
No Relationships to Disclose
 
Kenneth H. Yu
Employment - Memorial Sloan-Kettering Cancer Center
Consulting or Advisory Role - Ipsen
Research Funding - General Oncology (Inst); Ipsen; OncoC4 (Inst); Senhwa Biosciences (Inst)
 
Kimberly Perez
Consulting or Advisory Role - Celgene; Eisai; Helsinn Therapeutics/QED Therapeutics; Lantheus Medical Imaging
 
Amber N Habowski
No Relationships to Disclose
 
Robert C Grant
Consulting or Advisory Role - AstraZeneca; Eisai; Guardant Health; Ipsen; Knight Therapeutics; Pfizer
 
Sandra Fischer
No Relationships to Disclose
 
Andrew Aguirre
Stock and Other Ownership Interests - Kestrel Therapeutics; Riva Therapeutics
Honoraria - Phillips Gilmore Oncology
Consulting or Advisory Role - Alcon (I); Arrakis Therapeutics; AstraZeneca; Boehringer Ingelheim; Merck; Mirati Therapeutics; Nimbus Therapeutics; Plexium; Revolution Medicines; Riva Therapeutics; SERVIER; Syros Pharmaceuticals; T-Knife; Third Rock Ventures
Research Funding - Bristol-Myers Squibb/Celgene; Deerfield Management; Mirati Therapeutics; Novartis; Novo Ventures; Revolution Medicines; Syros Pharmaceuticals
 
Raymond Woo-Jun Jang
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis (Inst); Eisai; Ipsen; Ipsen; Novartis
Research Funding - AstraZeneca (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Craig E. Devoe
Honoraria - Vivacitas Oncology
Consulting or Advisory Role - Pfizer
 
Eileen M. O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); SERVIER (I); Tempus; Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Anna Dodd
No Relationships to Disclose
 
Brian M. Wolpin
Consulting or Advisory Role - Agenus; EcoR1 Capital; GRAIL; Ipsen; Mirati Therapeutics; Revolution Medicines; Third Rock Ventures
Research Funding - AstraZeneca (Inst); Harbinger Health (Inst); Lilly (Inst); Novartis (Inst); Revolution Medicines (Inst)
 
Xiang Y Ye
No Relationships to Disclose
 
Faiyaz Notta
No Relationships to Disclose
 
Steven Gallinger
No Relationships to Disclose
 
David A. Tuveson
Stock and Other Ownership Interests - Cygnal Therapeutics; Dunad Therapeutics; Leap Therapeutics; Mestag Therapeutics; Xilis
Consulting or Advisory Role - Cygnal Therapeutics; Dunad Therapeutics; Leap Therapeutics; Mestag Therapeutics; Xilis
Research Funding - Mestag Therapeutics; Ono Pharmaceutical
Patents, Royalties, Other Intellectual Property - anti-CA199 for pancreatitis (pending); We have filed a provisional use patent for 5B1 to use to treat pancreatitis. with MabVax, which was acquired by BionTech.